This article is more than 5 years old. Information may no longer be current.
Epsilon-aminocaproic acid not linked with reduced blood loss in PAO
Investigators of this study found administration of epsilon-aminocaproic acid had no significant impact on blood loss or allogenic transfusion among patients who underwent periacetabular osteotomy.
Researchers evaluated 93 patients who underwent unilateral periacetabular osteotomy for acetabular hip dysplasia. Of these patients, 50 received epsilon-aminocaproic acid (EACA). Investigators recorded demographics, autologous blood pre-donation, anesthetic type, intraoperative estimated blood loss, total blood loss, cell-saver utilization and transfusions.
Multiple regression analysis was used to assess correlations between EACA administration and the calculated estimated blood loss, cell-saver utilization, intraoperative estimated blood loss and the maximum postoperative hemoglobin. Investigators also used a post hoc power analysis which detected a 250 mL difference in the calculated estimated blood loss between the patient groups.
Results showed the groups were not significantly different with regard to demographics. Patients who received EACA and those who did not showed no significant differences in mean blood loss and allogenic transfusion rates. Investigators also noted groups were not significantly different with regard to cell-saver utilization, postoperative hemoglobin and intraoperative estimated blood loss. Due to a clinical practice change, patients who did not receive EACA had a higher rate of autologous blood use. ‒ by Monica Jaramillo
Disclosures: McLawhorn reports he is a board or committee member of the American Association of Hip and Knee Surgeons, and is on the editorial or governing board for the American Journal of Orthopedics. Please see the full study for a list of all other authors’ relevant financial disclosures.